Stem cell transplantation for Hodgkin's disease: A review of the literature

Research output: Contribution to journalArticle

Abstract

High-dose chemotherapy followed by autologous peripheral-blood stem cell transplantation has resulted in long-term disease-free survival of 30%-60% in selected patients with refractory and relapsed Hodgkin's disease. In addition, a significant reduction in early transplant-related mortality in more recent studies has led to the widespread acceptance of autografting. Comparatively few studies of allografting for Hodgkin's disease have been performed. Although no prospective randomized trials have been performed, historical results show a significantly lower relapse rate when allografting results are compared to autografting results. These results suggest that a graft-versus-Hodgkin's disease effect may exist. Unfortunately, the lower relapse rate following allografting is offset by higher transplant-related mortality. The use of low-intensity nonmyeloablative regimens for allografting may harness a graft-versus-Hodgkin's disease effect with less morbidity and mortality than that observed following conventional allografting.

Original languageEnglish
Pages (from-to)212-221
Number of pages10
JournalClinical Lymphoma
Volume2
Issue number4
Publication statusPublished - 2002

Fingerprint

Homologous Transplantation
Stem Cell Transplantation
Hodgkin Disease
Transplants
Autologous Transplantation
Mortality
Peripheral Blood Stem Cell Transplantation
Recurrence
Disease-Free Survival
Morbidity
Drug Therapy

Keywords

  • Allogeneic transplants
  • Autologous stem cell transplantation
  • Hodgkin's disease
  • Relapsed disease

ASJC Scopus subject areas

  • Cancer Research

Cite this

Stem cell transplantation for Hodgkin's disease : A review of the literature. / Carella, Angelo M.

In: Clinical Lymphoma, Vol. 2, No. 4, 2002, p. 212-221.

Research output: Contribution to journalArticle

@article{e1247a1cc4504346aa03fe296ff83a61,
title = "Stem cell transplantation for Hodgkin's disease: A review of the literature",
abstract = "High-dose chemotherapy followed by autologous peripheral-blood stem cell transplantation has resulted in long-term disease-free survival of 30{\%}-60{\%} in selected patients with refractory and relapsed Hodgkin's disease. In addition, a significant reduction in early transplant-related mortality in more recent studies has led to the widespread acceptance of autografting. Comparatively few studies of allografting for Hodgkin's disease have been performed. Although no prospective randomized trials have been performed, historical results show a significantly lower relapse rate when allografting results are compared to autografting results. These results suggest that a graft-versus-Hodgkin's disease effect may exist. Unfortunately, the lower relapse rate following allografting is offset by higher transplant-related mortality. The use of low-intensity nonmyeloablative regimens for allografting may harness a graft-versus-Hodgkin's disease effect with less morbidity and mortality than that observed following conventional allografting.",
keywords = "Allogeneic transplants, Autologous stem cell transplantation, Hodgkin's disease, Relapsed disease",
author = "Carella, {Angelo M.}",
year = "2002",
language = "English",
volume = "2",
pages = "212--221",
journal = "Clinical Lymphoma",
issn = "1526-9655",
publisher = "Cancer Information Group, LP",
number = "4",

}

TY - JOUR

T1 - Stem cell transplantation for Hodgkin's disease

T2 - A review of the literature

AU - Carella, Angelo M.

PY - 2002

Y1 - 2002

N2 - High-dose chemotherapy followed by autologous peripheral-blood stem cell transplantation has resulted in long-term disease-free survival of 30%-60% in selected patients with refractory and relapsed Hodgkin's disease. In addition, a significant reduction in early transplant-related mortality in more recent studies has led to the widespread acceptance of autografting. Comparatively few studies of allografting for Hodgkin's disease have been performed. Although no prospective randomized trials have been performed, historical results show a significantly lower relapse rate when allografting results are compared to autografting results. These results suggest that a graft-versus-Hodgkin's disease effect may exist. Unfortunately, the lower relapse rate following allografting is offset by higher transplant-related mortality. The use of low-intensity nonmyeloablative regimens for allografting may harness a graft-versus-Hodgkin's disease effect with less morbidity and mortality than that observed following conventional allografting.

AB - High-dose chemotherapy followed by autologous peripheral-blood stem cell transplantation has resulted in long-term disease-free survival of 30%-60% in selected patients with refractory and relapsed Hodgkin's disease. In addition, a significant reduction in early transplant-related mortality in more recent studies has led to the widespread acceptance of autografting. Comparatively few studies of allografting for Hodgkin's disease have been performed. Although no prospective randomized trials have been performed, historical results show a significantly lower relapse rate when allografting results are compared to autografting results. These results suggest that a graft-versus-Hodgkin's disease effect may exist. Unfortunately, the lower relapse rate following allografting is offset by higher transplant-related mortality. The use of low-intensity nonmyeloablative regimens for allografting may harness a graft-versus-Hodgkin's disease effect with less morbidity and mortality than that observed following conventional allografting.

KW - Allogeneic transplants

KW - Autologous stem cell transplantation

KW - Hodgkin's disease

KW - Relapsed disease

UR - http://www.scopus.com/inward/record.url?scp=0036225309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036225309&partnerID=8YFLogxK

M3 - Article

C2 - 11970760

AN - SCOPUS:0036225309

VL - 2

SP - 212

EP - 221

JO - Clinical Lymphoma

JF - Clinical Lymphoma

SN - 1526-9655

IS - 4

ER -